Preclinical formulations for discovery and toxicology: physicochemical challenges

Formulations play a key role in assessing the biological properties of a molecule during drug discovery. Maximising exposure is the primary objective in early animal experimentation, so that the pharmacokinetics, pharmacodynamics and toxicological signals can be put into context with the biological response to specific targets. Consistency in the exposure is also a key aspect, and effective formulation and drug delivery strategies are important to achieve this. Diversity in the physiology between various animal species, routes of administration and limitations posed by specific pharmacological models make formulation development that much more challenging. Poor physicochemical properties of compounds in the early stages need to be kept under consideration while screening for formulation vehicles. This review captures the various challenges posed at different stages of drug discovery for formulation of a compound to dose in animals. Approaches to formulations for various routes of administration are discussed. Limitations posed by the goals for various animal studies such as early efficacy studies, pharmacokinetic studies and toxicology studies are identified and some strategies are proposed. Physicochemical characterisations that are needed to select formulation vehicles as well as to identify potential issues are suggested.

[1]  S Sweetana,et al.  Solubility principles and practices for parenteral drug dosage form development. , 1996, PDA journal of pharmaceutical science and technology.

[2]  Dufresne Rg Skin necrosis from intravenously infused materials. , 1987 .

[3]  P. Gao,et al.  Development of supersaturatable self-emulsifying drug delivery system formulations for improving the oral absorption of poorly soluble drugs , 2006, Expert opinion on drug delivery.

[4]  Robin Hull,et al.  A good practice guide to the administration of substances and removal of blood, including routes and volumes , 2001, Journal of applied toxicology : JAT.

[5]  Norman J Barlow,et al.  The effect of commonly used vehicles on canine hematology and clinical chemistry values. , 2006, Journal of the American Association for Laboratory Animal Science : JAALAS.

[6]  Hyunyoung Jeong,et al.  Evaluation of Using Dog as an Animal Model to Study the Fraction of Oral Dose Absorbed of 43 Drugs in Humans , 2000, Pharmaceutical Research.

[7]  Beate Bittner,et al.  Intravenous administration of poorly soluble new drug entities in early drug discovery: the potential impact of formulation on pharmacokinetic parameters. , 2002, Current opinion in drug discovery & development.

[8]  S. Higuchi,et al.  Gastric pH profiles of beagle dogs and their use as an alternative to human testing. , 2000, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[9]  R. Hull Guideline limit volumes for dosing animals in the preclinical stage of safety evaluation , 1995, Human & experimental toxicology.

[10]  A. C. Eissens,et al.  The Effects of Cyclodextrins on the Disposition of Intravenously Injected Drugs in the Rat , 1991, Pharmaceutical Research.

[11]  I. Gómez-Orellana Strategies to improve oral drug bioavailability , 2005, Expert opinion on drug delivery.

[12]  R. Müller,et al.  Nanosuspensions as particulate drug formulations in therapy. Rationale for development and what we can expect for the future. , 2001, Advanced drug delivery reviews.

[13]  S. Yalkowsky,et al.  Studies in phlebitis. VI: Dilution-induced precipitation of amiodarone HCL. , 1993, Journal of parenteral science and technology : a publication of the Parenteral Drug Association.

[14]  S. Venkatesh,et al.  Role of the development scientist in compound lead selection and optimization. , 2000, Journal of pharmaceutical sciences.

[15]  K. Rex,et al.  Inhibition of interleukin-1 but not tumor necrosis factor suppresses neovascularization in rat models of corneal angiogenesis and adjuvant arthritis. , 2002, Arthritis and rheumatism.

[16]  T. Nagai,et al.  Enhancement of the oral bioavailability of cinnarizine in oleic acid in beagle dogs. , 1987, Journal of pharmaceutical sciences.

[17]  B. Ballard Biopharmaceutical considerations in subcutaneous and intramuscular drug administration. , 1968, Journal of pharmaceutical sciences.

[18]  P. Greengard,et al.  The route of absorption of intraperitoneally administered compounds. , 1971, The Journal of pharmacology and experimental therapeutics.

[19]  S. Benita,et al.  Self-emulsifying drug delivery systems (SEDDS) for improved oral delivery of lipophilic drugs. , 2004, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[20]  B. Bittner,et al.  The impact of co-solvents and the composition of experimental formulations on the pump rate of the ALZET osmotic pump. , 2000, International journal of pharmaceutics.

[21]  Finco Dr,et al.  Physiologic effects of rapid infusion of Ringer's lactate solution into dogs. , 1978 .

[22]  V. Claassen Neglected factors in pharmacology and neuroscience research , 1994 .

[23]  M. Schleimer,et al.  Potential inhibitory effects of formulation ingredients on intestinal cytochrome P450. , 2000, International journal of pharmaceutics.

[24]  Xujin Lu,et al.  pH-Dependent Dissolution in Vitro and Absorption in Vivo of Weakly Basic Drugs: Development of a Canine Model , 2005, Pharmaceutical Research.

[25]  E. Kerns,et al.  High throughput physicochemical profiling for drug discovery. , 2001, Journal of pharmaceutical sciences.

[26]  S. Yalkowsky,et al.  Combined effect of cosolvent and cyclodextrin on solubilization of nonpolar drugs. , 1999, Journal of pharmaceutical sciences.

[27]  J. Dressman,et al.  Influence of physicochemical properties on dissolution of drugs in the gastrointestinal tract. , 1997, Advanced drug delivery reviews.

[28]  Monique Alric,et al.  A Dynamic Artificial Gastrointestinal System for Studying the Behavior of Orally Administered Drug Dosage Forms Under Various Physiological Conditions , 2004, Pharmaceutical Research.

[29]  F. Lombardo,et al.  Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. , 2001, Advanced drug delivery reviews.

[30]  J. S. Lee,et al.  Biopharmaceutics of Didanosine in Humans and in a Model for Acid-Labile Drugs, the Pentagastrin-Pretreated Dog , 1993, Pharmaceutical Research.

[31]  L. Mawdesley-Thomas,et al.  The toxicity of dimethyl sulphoxide (DMSO) for the dog, pig, rat and rabbit. , 1975, Toxicology.

[32]  E. Masini,et al.  Histamine-releasing properties of Polysorbate 80in vitro andin vivo: correlation with its hypotensive action in the dog , 1985, Agents and Actions.

[33]  Y C Wang,et al.  Review of excipients and pH's for parenteral products used in the United States. , 1980, Journal of the Parenteral Drug Association.

[34]  Brian Samas,et al.  An intravenous formulation decision tree for discovery compound formulation development. , 2003, International journal of pharmaceutics.

[35]  D. Ritchie,et al.  The new pre-preclinical paradigm: compound optimization in early and late phase drug discovery. , 2001, Current topics in medicinal chemistry.

[36]  C. Lipinski Drug-like properties and the causes of poor solubility and poor permeability. , 2000, Journal of pharmacological and toxicological methods.

[37]  P A Wilkinson,et al.  Relative bioavailability of danazol in dogs from liquid-filled hard gelatin capsules. , 1999, International journal of pharmaceutics.

[38]  Roger A. Rajewski,et al.  Cyclodextrins: Their Future in Drug Formulation and Delivery , 1997, Pharmaceutical Research.

[39]  Bradley D. Anderson,et al.  Stable Supersaturated Aqueous Solutions of Silatecan 7-t-Butyldimethylsilyl-10-Hydroxycamptothecin via Chemical Conversion in the Presence of a Chemically Modified β-Cyclodextrin , 2002, Pharmaceutical Research.

[40]  B. Swanson Medical use of dimethyl sulfoxide (DMSO). , 1985, Reviews in clinical & basic pharmacology.

[41]  Gordon L Amidon,et al.  A Mechanistic Approach to Understanding the Factors Affecting Drug Absorption: A Review of Fundamentals , 2002, Journal of clinical pharmacology.

[42]  Susan A Charman,et al.  Alteration of the intravenous pharmacokinetics of a synthetic ozonide antimalarial in the presence of a modified cyclodextrin. , 2006, Journal of pharmaceutical sciences.

[43]  G. Sponer,et al.  Acute toxicity of various solvents in the mouse and rat. LD50 of ethanol, diethylacetamide, dimethylformamide, dimethylsulfoxide, glycerine, N-methylpyrrolidone, polyethylene glycol 400, 1,2-propanediol and Tween 20. , 1976, Arzneimittel-Forschung.

[44]  J. Meyer,et al.  Effect of hydroxypropylmethylcellulose on gastrointestinal transit and luminal viscosity in dogs. , 1991, Gastroenterology.

[45]  Abdul W Basit,et al.  Excipient effects on gastrointestinal transit and drug absorption in beagle dogs. , 2005, International journal of pharmaceutics.

[46]  L. Kinter,et al.  Characterization of maximal intravenous dose volumes in the dog (Canis familiaris). , 1993, General pharmacology.

[47]  P Langguth,et al.  Intestinal drug efflux: formulation and food effects. , 2001, Advanced drug delivery reviews.

[48]  Rainer H. Müller,et al.  Nanosuspensions for the formulation of poorly soluble drugs: I. Preparation by a size-reduction technique , 1998 .

[49]  T. Darby Safety evaluation of polymer materials. , 1987, Annual review of pharmacology and toxicology.

[50]  W. Curatolo,et al.  Physical chemical properties of oral drug candidates in the discovery and exploratory development settings , 1998 .

[51]  R. Löbenberg,et al.  Evaluation of Various Dissolution Media for Predicting In Vivo Performance of Class I and II Drugs , 1998, Pharmaceutical Research.

[52]  Colin W. Pouton,et al.  Self-Emulsifying Drug Delivery Systems: Formulation and Biopharmaceutic Evaluation of an Investigational Lipophilic Compound , 2004, Pharmaceutical Research.

[53]  Final Report on the Safety Assessment of Propylene Glycol and Polypropylene Glycols , 1994 .

[54]  Christopher T. Walsh,et al.  Drugs as materials: valuing physical form in drug discovery , 2004, Nature Reviews Drug Discovery.

[55]  G. Amidon,et al.  Comparison of gastrointestinal pH in dogs and humans: implications on the use of the beagle dog as a model for oral absorption in humans. , 1986, Journal of pharmaceutical sciences.

[56]  W. Charman,et al.  Lipid-based vehicles for the oral delivery of poorly water soluble drugs , 1997 .

[57]  Barrett E. Rabinow,et al.  Nanosuspensions in drug delivery , 2004, Nature Reviews Drug Discovery.

[58]  P. Raymond,et al.  Effect of dosing vehicle on the hepatotoxicity of CCl4 and nephrotoxicity of CHCl3 in rats. , 1997, Journal of toxicology and environmental health.

[59]  D. Culver,et al.  Physiologic effects of rapid infusion of Ringer's lactate solution into dogs. , 1978, American journal of veterinary research.

[60]  J. Chaumeil Micronization: a method of improving the bioavailability of poorly soluble drugs. , 1998, Methods and findings in experimental and clinical pharmacology.

[61]  B. D. Anderson,et al.  Solubilization of a tripeptide HIV protease inhibitor using a combination of ionization and complexation with chemically modified cyclodextrins. , 1994, Journal of pharmaceutical sciences.

[62]  Lawrence X. Yu An Integrated Model for Determining Causes of Poor Oral Drug Absorption , 1999, Pharmaceutical Research.

[63]  V. Baumans,et al.  Assessment of side effects induced by injection of different adjuvant/antigen combinations in rabbits and mice , 1998, Laboratory animals.

[64]  Alex Sparreboom,et al.  Role of Formulation Vehicles in Taxane Pharmacology , 2001, Investigational New Drugs.

[65]  N. El-Sherif,et al.  Hypotensive Action of Commercial Intravenous Amiodarone and Polysorbate 80 in Dogs , 1982, Journal of cardiovascular pharmacology.

[66]  Kap Lim,et al.  Solubilization of Thiazolobenzimidazole Using a Combination of pH Adjustment and Complexation with 2-Hydroxypropyl-β-Cyclodextrin , 1993, Pharmaceutical Research.

[67]  J. Dressman,et al.  Comparison of Canine and Human Gastrointestinal Physiology , 1986, Pharmaceutical Research.

[68]  B. Bittner,et al.  Formulations and related activities for the oral administration of poorly water-soluble compounds in early discovery animal studies: An overview of frequently applied approaches. Part 1 , 2002 .

[69]  C. Kibbey,et al.  An integrated process for measuring the physicochemical properties of drug candidates in a preclinical discovery environment. , 2001, Journal of pharmaceutical sciences.

[70]  Alexander V. Kabanov,et al.  Pluronic P85 Increases Permeability of a Broad Spectrum of Drugs in Polarized BBMEC and Caco-2 Cell Monolayers , 1999, Pharmaceutical Research.

[71]  C. Mitchell,et al.  Dimethylsulphoxide-induced serum hyperosmolality after cryopreserved stem-cell graft , 1994, The Lancet.

[72]  R. Hillman The subcutaneous space: a route for continuous administration of drugs? , 1983 .